Company profile
Pulmovant
Roivant Sciences subsidiary developing an inhaled sGC activator in-licensed from Bayer
Subsidiary of Roivant Sciences Ltd. (ROIV) · USA
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Soluble guanylate cyclaseSmall molecule | Hypertension Pulmonary Hypertension |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.